KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables: 2017-2025

Historic Receivables for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $14.1 million.

  • Aquestive Therapeutics' Receivables rose 20.92% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.7 million, marking a year-over-year increase of 24.53%. This contributed to the annual value of $9.8 million for FY2024, which is 13.78% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Receivables stood at $14.1 million, which was up 0.36% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Receivables ranged from a high of $22.6 million in Q2 2022 and a low of $6.8 million during Q4 2022.
  • For the 3-year period, Aquestive Therapeutics' Receivables averaged around $11.4 million, with its median value being $11.4 million (2023).
  • In the last 5 years, Aquestive Therapeutics' Receivables tumbled by 62.24% in 2022 and then surged by 83.59% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Receivables (Quarterly) stood at $18.1 million in 2021, then tumbled by 62.24% to $6.8 million in 2022, then skyrocketed by 66.39% to $11.4 million in 2023, then declined by 13.78% to $9.8 million in 2024, then rose by 20.92% to $14.1 million in 2025.
  • Its Receivables was $14.1 million in Q3 2025, compared to $14.1 million in Q2 2025 and $12.7 million in Q1 2025.